L9787
L-655,708
≥98% (HPLC), powder
别名:
L-655708, （S）-11，12，13，13a-四氢-7-甲氧基-9-氧代-9H-咪唑并[1，5-a]吡咯并[2，1-c][1，4]苯并二氮杂-1-羧酸乙酯
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C18H19N3O4
化学文摘社编号:
分子量:
341.36
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
产品名称
L-655,708, ≥98% (HPLC), powder
InChI
1S/C18H19N3O4/c1-3-25-18(23)15-16-14-5-4-8-20(14)17(22)12-9-11(24-2)6-7-13(12)21(16)10-19-15/h6-7,9-10,14H,3-5,8H2,1-2H3/t14-/m0/s1
SMILES string
CCOC(=O)c1ncn2-c3ccc(OC)cc3C(=O)N4CCCC4c12
InChI key
YKYOQIXTECBVBB-AWEZNQCLSA-N
assay
≥98% (HPLC)
form
powder
solubility
DMSO: ≥6.0 mg/mL (Warmed)
H2O: insoluble
originator
Merck & Co., Inc., Kenilworth, NJ, U.S.
Quality Level
Gene Information
human ... GABRA5(2558)
Biochem/physiol Actions
L-655，708是 α5 γ-氨基丁酸A型（GABAA）受体的反向激动剂。它具有增加大鼠认知的能力。
含有α5个亚基的GABAA受体苯二氮平类药物位点的配体。
对含有α5个亚基的GABAA 受体的苯二氮平类药物位点具有选择性的新型配体。
Application
L-655，708已被用作α5 GABAA受体反向激动剂，以剂量依赖的方式抑制异丙酚的辨别刺激。
Features and Benefits
该化合物是由Merck & Co., Inc., Kenilworth, NJ, U.S.开发的。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单， 请单击此处。
该化合物是神经科学研究推荐产品。点击此处 ，查看更多神经科学精选产品。想要了解有关生物活性小分子在其他研究领域应用的更多信息，请访问 sigma.com/discover-bsm。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
M Xue et al.
European journal of pain (London, England), 21(6), 1061-1071 (2017-02-02)
γ-Aminobutyric acid (GABA) type A receptors (GABA The C fibre-evoked field potentials were recorded in superficial dorsal horn of spinal cord, and the effects of α5-GABA Inhibition of α5-GABA α5-GABA Tonic inhibition generated by α5-GABA
C Sur et al.
Molecular pharmacology, 54(5), 928-933 (1998-11-06)
The gamma-aminobutyric acid (GABA)A receptor is a hetero-oligomer consisting of five subunits, the combination of which confers unique pharmacological properties to the receptor. To understand the physiological role of native GABAA receptors, it is critical to determine their subunit compositions.
L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors
Atack JR, et al.
Neuropharmacology, 51(6), 1023-1029 (2006)
Flavia R Carreno et al.
The international journal of neuropsychopharmacology, 20(6), 504-509 (2017-03-25)
Selective augmentation of hippocampal activity in ways similar to that caused by ketamine may have therapeutic advantages over ketamine, which has psychotomimetic and reinforcing effects likely due to effects outside the hippocampus (i.e., off-target effects). Here we evaluated the antidepressant-like
[3H]L-655,708, a novel ligand selective for the benzodiazepine site of GABAA receptors which contain the α5 subunit.
Quirk, K., et al.
Neuropharmacology, 356, 1331-1335 (1996)
商品
DISCOVER Bioactive Small Molecules for Neuroscience
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持